Encompass Health Corporation · EHC · FY2026 Q1 · Calendar Q2 2026

EHC raises 2026 outlook as capacity expansion targets strong rehab demand

The supplied analysis supports a constructive operating thesis for EHC: demand for inpatient rehabilitation remains strong, and capacity additions plus improved labor performance support continued growth. The thesis depends on converting high occupancy into profitable new capacity while managing reimbursement changes, Medicare Advantage dynamics, and rising capital needs.

Reported After market closeNYSEHealthcare $13.41B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.60 Consensus $1.51
EPS surprise +6.0% Reported versus consensus
Reported revenue $1.59B Consensus $1.57B
Revenue surprise +1.2% Reported versus consensus

Market reaction

event-close to next-session close
Stock move +7.5% Event window
SPY move +0.3% Same window
Abnormal move +7.2% Stock minus SPY
Volume 1.7× Versus trailing sessions
Subsequent drift -4.4% Up to 20 sessions
EHCSPY benchmark

Ask FN2 about EHC FY2026 Q1

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior quarter, management moved from maintained to raised guidance. The current analysis adds a 17.8% RN-turnover result, a new 49-bed hospital, plans for seven additional hospitals and further bed additions, and early evidence from an admit-and-appeal pilot.

Guidance delta

Management raised 2026 revenue, adjusted EBITDA, and EPS guidance after Q1.

Key takeaways

  • Q1 revenue and EBITDA exceeded expectations, supporting a 2026 guidance increase.
  • RN turnover reached 17.8%, the lowest level since 2012, alongside career-ladder and centralized hiring efforts.
  • Expansion includes a new 49-bed hospital, seven planned hospitals totaling 340 beds, and additional existing-site capacity.
  • Occupancy above 90% in high-growth markets is accelerating new-bed planning.
  • Medicare Advantage penetration has plateaued or receded, while an admit-and-appeal pilot is showing early promise.

Management priorities

  • Add hospitals and beds in high-growth markets.
  • Scale small-format hospitals and the hub-and-spoke model.
  • Sustain lower turnover through career-ladder and talent-acquisition programs.
  • Evaluate and expand the Medicare Advantage admit-and-appeal pilot.
  • Manage TEAM, RCD, and other reimbursement changes.

Follow EHC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
EHC REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $1B Q4 '23 actual $1B, beat Q1 '24 estimate $1B Q1 '24 actual $1B, beat Q2 '24 estimate $1B Q2 '24 actual $1B, match Q3 '24 estimate $1B Q3 '24 actual $1B, miss Q2 '25 estimate $1B Q2 '25 actual $1B, beat Q3 '25 estimate $1B Q3 '25 actual $1B, miss Q4 '25 estimate $2B Q4 '25 actual $2B, beat Q1 '26 estimate $2B Q1 '26 actual $2B, beat Q2 '26 estimate $2B Q2 '26 actual $2B, beat Q3 '26 estimate $2B Q3 '26 actual $2B, beat Q4 '26 estimate $2B Q1 '27 estimate $2B Q2 '27 estimate $2B Q3 '27 estimate $2B
Show less

Analyst Consensus ?

ConsensusBuy26 ratings
Bullish2284.6%
Neutral311.5%
Bearish13.9%

Analyst 52W Price Targets

$135.9Current
$83Low
$125.13Average
$165High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
UBS Buy BuyMaintainOct 30, 2026
Truist Securities Buy BuyMaintainOct 30, 2026
TD Cowen Buy BuyMaintainOct 30, 2026
Keybanc Overweight OverweightMaintainOct 30, 2026
Barclays Overweight OverweightMaintainOct 29, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $135.9. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Raymond JamesAndrew Cooper$155$135.9 +14.1%Oct 30, 2026
UBSAnalyst unavailable$165$131.49 +21.4%Oct 30, 2026
KeyBancMatthew Gillmor$150$131.49 +10.4%Oct 30, 2026
Truist FinancialDavid MacDonald$156$131.49 +14.8%Oct 30, 2026
BarclaysAnalyst unavailable$151$122.09 +11.1%Oct 29, 2026
See 20 more

Track every rating change on EHC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes. The company's operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis. This care is designed for individuals recuperating from significant health challenges such as strokes, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment primarily serves the Southeast and Texas regions.…

Historical context

All EHC earnings

Healthcare peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the EHC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-11-01T12:10:42.058420+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T12:10:42.055241+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.